ABSTRACT
Treatment plan: Sixty women refered to Oncology Department, Zagazig University Hospitals and Alexandria university Hospital with stages III and IV ovarian cancer and with measurable disease at least one centimeter as a residual after any surgical procedure. Thirty patients in the historical standard-therapy group [group A] were previously received cyclophosphamide [750mg/rn2 I. V] and cisplatin [75 mg/m2 I. V. infusion] every three weeks for a total of six cycles. Data were collected from files and from survived patients under follow up. Thirty patients in the experimental group [group B] received paclitexel [135 mg/m2 I. V. infusion over a period of three hours] and cisplatin [75mg/m2 I. V infusion] every three weeks for a total of six cycles. The overall response rate 83.4% was in group "B" versus 66.7% in group "A" [P.>0.05] Complete clinical responses were more frequent among women in group "B" [56.7%] than among those in group "A" [26.7%] P.>0.05. Seven women out of 17 [41.2%] in group "B" showed negative pathological results after laparotomy versus 2 out of 8 [25%] in group "A The overall survival rate was found to be 46.7% in group "A" versus 63.3% in group "B" with a median follow-up period of 28 months and 26 months respectively [P>0.05]. The progression-free survival in the same periods was 13.3% in group "A" versus 36.7% in group "B" [P<0.05]. Paclitaxel and cisplatin used as a first line therapy improves complete clinical response, overall survival, and progression-free survival rates in women with advanced stages [III and VI] ovarian cancer who have neasurable residual masses